LUNG-MAP
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
- NCT04173507 ↗
- Completed
- SWOG Cancer Research Network
- Focused
We haven't built an HCP commentary report on LUNG-MAP (talazoparib plus avelumab in STK11-mutated advanced non-squamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LUNG-MAP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Avelumab; Talazoparib; Talazoparib Tosylate
- Arms
- Treatment (talazoparib, avelumab) · Experimental
- Enrollment
- 47
- Primary outcomes
- Objective Response Rate (ORR)
- Disease Control Rate at 12 Weeks (DCR12)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Feb 14, 2020
- Primary completion
- Nov 24, 2021
- Results posted
- Yes
- Registry record
- NCT04173507 · updated Sep 3, 2024